Faecal butyrate · people with CKD
1 finding from 1 review
Faecal total short‐chain fatty acids · people with CKD
1 finding from 1 review
Faecal indoles · people with CKD
1 finding from 1 review
Faecal P‐cresol · people with CKD
1 finding from 1 review
Graft function · people with CKD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Graft infection · people with CKD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Beck Depression Inventory (BDI); higher score means more depression · men and women with end‐stage kidney disease
1 finding from 1 review
Beck Depression Inventory (BDI); higher score means more depression · people with CKD
It is very uncertain whether summary of findings: acupressure changes depression Beck Depression Inventory (BECK) (median compared with control (very low certainty).
1 finding from 1 review
Dizziness or hypotension · dialysis patients with depression
1 finding from 1 review
Nausea · dialysis patients with depression
1 finding from 1 review
Sexual dysfunction ‐ not reported · dialysis patients with depression
1 finding from 1 review
All‐cause mortality · dialysis patients with depression
1 finding from 1 review
Death at final · primary membranous nephropathy in adults with nephrotic syndrome
Immunosuppressive treatment showed no clear difference in death at final compared with placebo/no treatment/non‐immunosuppressive supportive treatment (moderate certainty).
1 finding from 1 review
End‐stage renal disease · primary membranous nephropathy in adults with nephrotic syndrome
Immunosuppressive treatment probably leads to lower end‐stage kidney disease at final compared with placebo/no treatment/non‐immunosuppressive supportive treatment (moderate certainty).
1 finding from 1 review
Total remission (complete or partial) at final · primary membranous nephropathy in adults with nephrotic syndrome
Immunosuppressive treatment probably leads to higher total remission (complete or partial) at final compared with placebo/no treatment/non‐immunosuppressive supportive treatment (moderate certainty).
1 finding from 1 review
Complete remission · primary membranous nephropathy in adults with nephrotic syndrome
Immunosuppressive treatment probably leads to higher complete remission at final compared with placebo/no treatment/non‐immunosuppressive supportive treatment (moderate certainty).
1 finding from 1 review
Relapse · primary membranous nephropathy in adults with nephrotic syndrome
Immunosuppressive treatment may leads to higher recurrence of disease (relapse) at final compared with placebo/no treatment/non‐immunosuppressive supportive treatment (low certainty).
1 finding from 1 review
100% increase in SCr at final · primary membranous nephropathy in adults with nephrotic syndrome
Immunosuppressive treatment probably leads to lower 100% increase in serum creatinine at final compared with placebo/no treatment/non‐immunosuppressive supportive treatment (moderate certainty).
1 finding from 1 review
Adverse events ‐ temporary or permanent discontinuation/hospitalisation at final · primary membranous nephropathy in adults with nephrotic syndrome
Immunosuppressive treatment probably leads to higher adverse events: temporary/permanent discontinuation or… compared with placebo/no treatment/non‐immunosuppressive supportive treatment (moderate certainty).
1 finding from 1 review
Adverse events: infection at 3 years · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether immunosuppressive treatment changes adverse events: infection at 3 years compared with placebo/no treatment/non‐immunosuppressive supportive treatment (very low certainty).
1 finding from 1 review